Sanofi Poised To File Isatuximab In Multiple Myeloma, Going Up Against J&J's Darzalex

 
• By Jessica Merrill

Isatuximab could be the next building block in Sanofi's ambitions to rebuild in oncology. The CD38-targeting antibody extended PFS in relapsed/refractory multiple myeloma in combination with Celgene's Pomalyst and dexamethasone.

Open Book Of prostate multiple myeloma, Conceptual Image - Image

More from R&D

More from Scrip